Avid Bioservices Inc (CDMO)

[md1225]

Bevacizumab is a monoclonal, recombinant, humanized murine antibody targeted at vascular endothelial growth factor (VEGF). In 2005, the Eastern Oncology Cooperative Group (ECOG) reported the results of the first randomized, phase 3 trial of carboplatin and paclitaxel ± bevacizumab in patients with chemotherapy-naïve, recurrent or metastatic, nonsquamous NSCLC (E4599). Median progression-free survival and overall survival increased from 4.5 and 10.3 months in the chemotherapy alone treatment arm, respectively, to 6.2 and 12.3 months in the chemotherapy plus bevacizumab treatment arm (P < .05).11 These results led to approval of the carboplatin, paclitaxel, and bevacizumab


This is the final data set.